Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has appointed Justin Cohen as an independent director to its Board and Audit Committee member. Cohen brings extensive experience in brand development, sales, and marketing from his roles at various companies.
As former Chief Marketing and Chief Commercial Officer at Psycho Bunny, Cohen led a tenfold revenue increase over three years through retail expansion and digital acceleration. His experience includes leadership positions at Keurig Dr Pepper, Google, ALDO Group, and Sony Music. Currently, he serves as a senior executive at Cosmetic Physician Partners, overseeing marketing across 55+ U.S. clinics.
The appointment aligns with Cannara's strategy to position its three flagship brands – Tribal, Nugz, and Orchid CBD – as leading cannabis brands in Canada. The company operates two mega facilities in Québec spanning over 1,650,000 sq. ft.
Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) ha nominato Justin Cohen come direttore indipendente del suo Consiglio di Amministrazione e membro del Comitato di Audit. Cohen porta con sé una vasta esperienza nello sviluppo del marchio, nelle vendite e nel marketing, acquisita attraverso i suoi ruoli in diverse aziende.
In qualità di ex Chief Marketing e Chief Commercial Officer di Psycho Bunny, Cohen ha guidato un aumento del fatturato dieci volte superiore in tre anni grazie all'espansione al dettaglio e all'accelerazione digitale. La sua esperienza include posizioni di leadership presso Keurig Dr Pepper, Google, ALDO Group e Sony Music. Attualmente, ricopre il ruolo di dirigente senior presso Cosmetic Physician Partners, supervisionando il marketing in oltre 55 cliniche negli Stati Uniti.
La nomina è in linea con la strategia di Cannara di posizionare i suoi tre marchi di punta – Tribal, Nugz e Orchid CBD – come marchi leader nel settore della cannabis in Canada. L'azienda gestisce due mega strutture in Québec che si estendono per oltre 1.650.000 piedi quadrati.
Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) ha nombrado a Justin Cohen como director independiente de su Junta y miembro del Comité de Auditoría. Cohen aporta una amplia experiencia en desarrollo de marcas, ventas y marketing a partir de sus roles en diversas empresas.
Como ex Director de Marketing y Director Comercial de Psycho Bunny, Cohen lideró un aumento de ingresos diez veces mayor en tres años a través de la expansión minorista y la aceleración digital. Su experiencia incluye posiciones de liderazgo en Keurig Dr Pepper, Google, ALDO Group y Sony Music. Actualmente, se desempeña como ejecutivo senior en Cosmetic Physician Partners, supervisando el marketing en más de 55 clínicas en EE. UU.
La designación se alinea con la estrategia de Cannara para posicionar sus tres marcas insignia – Tribal, Nugz y Orchid CBD – como marcas líderes de cannabis en Canadá. La compañía opera dos mega instalaciones en Quebec que abarcan más de 1,650,000 pies cuadrados.
카나라 바이오텍 (TSXV: LOVE) (OTCQB: LOVFF)는 저스틴 코헨을 독립 이사로 임명하고 감사위원회 위원으로 선출했습니다. 코헨은 다양한 회사에서의 경력을 통해 브랜드 개발, 판매 및 마케팅에 대한 광범위한 경험을 제공합니다.
사이코 버니의 전 마케팅 최고 책임자 및 상업 최고 책임자로서 코헨은 소매 확장 및 디지털 가속화를 통해 3년 동안 수익을 10배 증가시켰습니다. 그의 경험에는 Keurig Dr Pepper, Google, ALDO Group 및 Sony Music에서의 리더십 직책이 포함됩니다. 현재 그는 Cosmetic Physician Partners의 수석 임원으로 재직하며 미국 내 55개 이상의 클리닉의 마케팅을 감독하고 있습니다.
이번 임명은 카나라의 세 가지 주력 브랜드인 트라이벌, 너그즈, 오키드 CBD를 캐나다의 선도적인 대마초 브랜드로 자리매김하기 위한 전략과 일치합니다. 이 회사는 퀘벡에 1,650,000평방피트 이상의 면적을 가진 두 개의 메가 시설을 운영하고 있습니다.
Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) a nommé Justin Cohen en tant que directeur indépendant au sein de son Conseil d'Administration et membre du Comité d'Audit. Cohen apporte une vaste expérience en développement de marque, ventes et marketing acquise au cours de ses rôles dans diverses entreprises.
En tant qu'ancien directeur marketing et directeur commercial chez Psycho Bunny, Cohen a conduit à une augmentation des revenus multipliée par dix en trois ans grâce à l'expansion du commerce de détail et à l'accélération numérique. Son expérience comprend des postes de direction chez Keurig Dr Pepper, Google, ALDO Group et Sony Music. Actuellement, il occupe un poste de cadre supérieur chez Cosmetic Physician Partners, supervisant le marketing dans plus de 55 cliniques aux États-Unis.
Cette nomination s'inscrit dans la stratégie de Cannara visant à positionner ses trois marques phares – Tribal, Nugz et Orchid CBD – comme des marques de cannabis leaders au Canada. L'entreprise exploite deux méga installations au Québec s'étendant sur plus de 1 650 000 pieds carrés.
Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) hat Justin Cohen als unabhängigen Direktor in seinen Vorstand und als Mitglied des Prüfungsausschusses ernannt. Cohen bringt umfangreiche Erfahrungen in der Markenentwicklung, im Vertrieb und im Marketing aus seinen Tätigkeiten in verschiedenen Unternehmen mit.
Als ehemaliger Chief Marketing und Chief Commercial Officer bei Psycho Bunny führte Cohen in drei Jahren durch Einzelhandelsausbau und digitale Beschleunigung zu einer zehnfachen Umsatzsteigerung. Zu seinen Erfahrungen zählen Führungspositionen bei Keurig Dr Pepper, Google, ALDO Group und Sony Music. Derzeit ist er als leitender Angestellter bei Cosmetic Physician Partners tätig und überwacht das Marketing in über 55 Kliniken in den USA.
Die Ernennung steht im Einklang mit der Strategie von Cannara, ihre drei Hauptmarken – Tribal, Nugz und Orchid CBD – als führende Cannabis-Marken in Kanada zu positionieren. Das Unternehmen betreibt zwei Mega-Anlagen in Québec mit einer Gesamtfläche von über 1.650.000 Quadratfuß.
- Appointment of experienced executive with proven track record in brand development and revenue growth
- Strategic addition to support expansion of three flagship cannabis brands
- New director brings successful experience scaling revenues (10x growth at previous company)
- Addition of marketing expertise to support market expansion in Canada
- None.
MONTREAL, March 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce the appointment of Mr. Justin Cohen to its board of directors (the “Board”) as an independent director. Mr. Cohen will also serve as a member of the Audit Committee.
Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention.
Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities.
Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics.
“We are thrilled to welcome Justin to our Board,” said Zohar Krivorot, CEO of Cannara. “His expertise in brand building, digital transformation, and consumer engagement aligns perfectly with Cannara’s vision to execute our strategy of positioning our three flagship brands – Tribal, Nugz, and Orchid CBD – as Canada’s leading cannabis brands. His strategic leadership will be invaluable as we scale our operations and expand our brand equity and market presence in Canada.”
"I am honored to join Cannara’s Board of Directors at such an exciting time,” said Mr. Justin Cohen. “Cannara has established itself as a leader in the cannabis industry with a strong commitment to quality, innovation, and accessibility. I look forward to contributing my experience in brand strategy and digital transformation to support Cannara’s continued success and expansion."
CONTACT
| Nicholas Sosiak, CPA, CA Chief Financial Officer nick@cannara.ca | Zohar Krivorot President & Chief Executive Officer zohar@cannara.ca |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ABOUT CANNARA
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.
CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION
This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements with respect to Cannara future performance, market growth, and business expansion.
Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.
In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.
Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.
FAQ
What experience does Justin Cohen bring to Cannara Biotech (LOVFF)?
How large are Cannara Biotech's (LOVFF) production facilities?
What are Cannara Biotech's (LOVFF) main cannabis brands?
What positions will Justin Cohen hold at Cannara Biotech (LOVFF)?
